Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.

discontinuation disease-modifying therapy multiple sclerosis switch

Journal

Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242

Informations de publication

Date de publication:
2024
Historique:
received: 27 06 2023
accepted: 14 02 2024
medline: 1 4 2024
pubmed: 1 4 2024
entrez: 1 4 2024
Statut: epublish

Résumé

The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice. To compare switchers and non-switchers, characterize the first DMT switch and identify reasons and predictors for switching the first DMT. Data on 2722 PwMS from the German MS Registry were retrospectively analyzed regarding sociodemographic/clinical differences between 1361 switchers (PwMS discontinuing the first DMT) and non-switchers matched according to age, sex, and observation period. Frequencies of first and second DMTs were calculated and switch reasons identified. Predictors for DMT switches were revealed using univariable and multivariable regression models. Switchers and non-switchers differed significantly regarding time to first DMT, education, calendar period of the first DMT start (2014-2017 The initial use of MME DMTs was among the strongest predictors of DMT discontinuation in a large German retrospective MS cohort, arguing for the need for prospective treatment strategy trials, not only but also on the initial broad use of HE DMTs in PwMS.

Sections du résumé

Background UNASSIGNED
The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice.
Objective UNASSIGNED
To compare switchers and non-switchers, characterize the first DMT switch and identify reasons and predictors for switching the first DMT.
Methods UNASSIGNED
Data on 2722 PwMS from the German MS Registry were retrospectively analyzed regarding sociodemographic/clinical differences between 1361 switchers (PwMS discontinuing the first DMT) and non-switchers matched according to age, sex, and observation period. Frequencies of first and second DMTs were calculated and switch reasons identified. Predictors for DMT switches were revealed using univariable and multivariable regression models.
Results UNASSIGNED
Switchers and non-switchers differed significantly regarding time to first DMT, education, calendar period of the first DMT start (2014-2017
Conclusion UNASSIGNED
The initial use of MME DMTs was among the strongest predictors of DMT discontinuation in a large German retrospective MS cohort, arguing for the need for prospective treatment strategy trials, not only but also on the initial broad use of HE DMTs in PwMS.

Identifiants

pubmed: 38560408
doi: 10.1177/17562864241239740
pii: 10.1177_17562864241239740
pmc: PMC10981260
doi:

Types de publication

Journal Article

Langues

eng

Pagination

17562864241239740

Informations de copyright

© The Author(s), 2024.

Auteurs

Niklas Frahm (N)

German MS Registry, MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH [MSFP]), Krausenstr. 50, Hannover, Niedersachsen 30171, Germany.

David Ellenberger (D)

German MS Registry, MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH [MSFP]), Hannover, Germany.

Alexander Stahmann (A)

German MS Registry, MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH [MSFP]), Hannover, Germany.

Firas Fneish (F)

German MS Registry, MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH [MSFP]), Hannover, Germany.

Daniel Lüftenegger (D)

Biogen GmbH, München, Germany.

Hans C Salmen (HC)

Biogen GmbH, München, Germany.

Ksenija Schirduan (K)

Biogen GmbH, München, Germany.

Tom P A Schaak (TPA)

Biogen GmbH, München, Germany.

Peter Flachenecker (P)

Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany.

Christoph Kleinschnitz (C)

Department of Neurology and Center of Translational and Behavioral Neurosciences (C-TNBS), University Hospital Essen, Essen, Germany.

Friedemann Paul (F)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany.

Dagmar Krefting (D)

Department of Medical Informatics, University Medical Center Göttingen, Göttingen, Germany.

Uwe K Zettl (UK)

Department of Neurology, Neuroimmunological Section, University Medical Center of Rostock, Rostock, Germany.

Melanie Peters (M)

German MS Registry, Gesellschaft für Versorgungsforschung mbH (Society for Health Care Research [GfV]), Hannover, Germany.

Clemens Warnke (C)

Department of Neurology, Medical Faculty, University Hospital of Cologne, Cologne, Germany.

Classifications MeSH